{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omega-3+fatty+acid+%28Eicosapentaenoic+acid%29&page=8",
    "query": {
      "intervention": "Omega-3 fatty acid (Eicosapentaenoic acid)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 204,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omega-3+fatty+acid+%28Eicosapentaenoic+acid%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omega-3+fatty+acid+%28Eicosapentaenoic+acid%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:14:39.215Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00498368",
      "title": "Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous Rituximab",
          "type": "DRUG"
        },
        {
          "name": "ACE/ARB",
          "type": "DRUG"
        },
        {
          "name": "Omega-3 Fatty Acid Fish Oil Supplement",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 34,
      "start_date": "2009-02",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Rochester, Minnesota • New York, New York + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498368"
    },
    {
      "nct_id": "NCT03383835",
      "title": "Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Omega-3 Supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Lauren Nye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 40 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2018-02-05",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-05-23",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Westwood, Kansas",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03383835"
    },
    {
      "nct_id": "NCT02113163",
      "title": "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Metformin Eicosapentaenoate",
          "type": "DRUG"
        },
        {
          "name": "Metformin HCl and Vascepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thetis Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113163"
    },
    {
      "nct_id": "NCT01908907",
      "title": "Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prematurity"
      ],
      "interventions": [
        {
          "name": "DHA oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "(MCT) Control oil",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Sanford Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Weeks",
        "maximum_age": "33 Weeks",
        "sex": "ALL",
        "summary": "24 Weeks to 33 Weeks"
      },
      "enrollment_count": 60,
      "start_date": "2012-10",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2019-03-21",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01908907"
    },
    {
      "nct_id": "NCT00344721",
      "title": "A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "Omega-3 fatty acid supplement",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 42,
      "start_date": "2004-09",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2018-05-14",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00344721"
    },
    {
      "nct_id": "NCT03350906",
      "title": "Enhancing Adaptations to Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "n3-PUFA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Body Composition Scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "20 Years to 85 Years"
      },
      "enrollment_count": 63,
      "start_date": "2018-01-01",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03350906"
    },
    {
      "nct_id": "NCT02947100",
      "title": "Omega-3 Fatty Acids in Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "SCD-Omegatex™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robin E. Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "8 Years to 25 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-25",
      "completion_date": "2018-10-15",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947100"
    },
    {
      "nct_id": "NCT01633177",
      "title": "Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Omega-3 fatty acid (fish oil)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D3 placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Fish oil placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22220,
      "start_date": "2011-11",
      "completion_date": "2024-05-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633177"
    },
    {
      "nct_id": "NCT00944229",
      "title": "The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LOVAZA (Omega-3)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2010-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-05-25",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00944229"
    },
    {
      "nct_id": "NCT00244816",
      "title": "Taxoprexin® Treatment for Advanced Eye Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Taxoprexin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Regent, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-14T14:14:39.215Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244816"
    }
  ]
}